Endothelin antagonism in end-organ damage of spontaneously hypertensive rats - Comparison with angiotensin-converting enzyme inhibition and calcium antagonism

被引:74
|
作者
Karam, H
Heudes, D
Bruneval, P
Gonzales, MF
Loffler, BM
Clozel, M
Clozel, JP
机构
[1] F HOFFMANN LA ROCHE & CO LTD,PRECLIN RES,DIV PHARMA,CH-4002 BASEL,SWITZERLAND
[2] HOP BROUSSAIS,INSERM U430,F-75674 PARIS,FRANCE
[3] INSERM U367,PARIS,FRANCE
关键词
angiotensin II; endothelin; kidney; mibefradil; bosentan; enalapril;
D O I
10.1161/01.HYP.28.3.379
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
High blood pressure results in cardiac hypertrophy and fibrosis, increased thickness and stiffness of large artery walls, and decreased renal function. The objective of our study was to assess the role of endothelin, angiotensin II, and high blood pressure in the end-organ damage observed in spontaneously hypertensive rats (SHR). For this purpose, SHR were treated for 10 weeks with either a mixed endothelin-A and endothelin-B receptor antagonist, bosentan (100 mg/kg per day), an angiotensin-converting enzyme inhibitor, enalapril (10 mg/kg per day), or a long-acting calcium antagonist, mibefradil (20 mg/kg per day). A group of SHR was left untreated, and a group of normotensive Wistar rats was used as control. At the end of treatment, maximal coronary blood flow was measured in isolated perfused hearts. Cardiac hypertrophy and fibrosis, aortic medial thickness, and extracellular matrix content were evaluated by quantitative morphometry. Proteinuria and urea and creatinine clearances were measured, and renal histopathology was assessed. SHR exhibited cardiac hypertrophy, perivascular fibrosis, and decreased maximal coronary blood Bow. Aortic medial thickness was increased, whereas elastin density was decreased. Finally, SHR showed decreased urinary excretion and decreased urea and creatinine clearances. No renal histological lesions were observed. Although bosentan did not affect blood pressure, it normalized renal function and slightly decreased left ventricular hypertrophy and fibrosis. Enalapril and mibefradil were both effective in significantly decreasing blood pressure, left ventricular hypertrophy, and aortic medial thickness and improving coronary blood flow, but in contrast to busentan, they did not improve creatinine clearance. The conclude that in SHR, high blood pressure sure plays a major role in end-organ damage and that endothelin may partly mediate renal dysfunction and cardiac remodeling independently of a direct hemodynamic effect.
引用
收藏
页码:379 / 385
页数:7
相关论文
共 50 条
  • [1] Renal endothelin system in diabetes: Comparison of angiotensin-converting enzyme inhibition and endothelin-A antagonism
    Hocher, B
    Lun, A
    Priem, F
    Neumayer, HH
    Raschack, M
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1998, 31 : S492 - S495
  • [2] Additive hypotensive and anti-albuminuric effects of angiotensin-converting enzyme inhibition and angiotensin receptor antagonism in diabetic spontaneously hypertensive rats
    Cao, ZM
    Bonnet, F
    Davis, B
    Allen, TJ
    Cooper, ME
    CLINICAL SCIENCE, 2001, 100 (06) : 591 - 599
  • [3] Angiotensin-converting Enzyme Is a Modifier of Hypertensive End Organ Damage
    Liu, Xiaojun
    Bellamy, Christopher O. C.
    Bailey, Matthew A.
    Mullins, Linda J.
    Dunbar, Donald R.
    Kenyon, Christopher J.
    Brooker, Gillian
    Kantachuvesiri, Surasak
    Maratou, Klio
    Ashek, Ali
    Clark, Allan F.
    Fleming, Stewart
    Mullins, John J.
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2009, 284 (23) : 15564 - 15572
  • [4] Effect of dual angiotensin converting enzyme/neutral endopeptidase inhibition, angiotensin converting enzyme inhibition, or AT1 antagonism on coronary microvasculature in spontaneously hypertensive rats
    Pu, Q
    Larouche, I
    Schiffrin, EL
    AMERICAN JOURNAL OF HYPERTENSION, 2003, 16 (11) : 931 - 937
  • [5] Additional hypotensive effect of endothelin-1 receptor antagonism in hypertensive dogs under angiotensin-converting enzyme inhibition
    Donckier, JE
    Massart, PE
    Hodeige, D
    VanMechelen, H
    Clozel, JP
    Laloux, O
    Ketelslegers, JM
    Charlier, AA
    Heyndrickx, GR
    CIRCULATION, 1997, 96 (04) : 1250 - 1256
  • [6] Chronic angiotensin-converting enzyme inhibition and angiotensin II antagonism in rats with chronic renal failure
    Yoshida, K
    Xu, HL
    Kawamura, T
    Ji, LN
    Kohzuki, M
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2002, 40 (04) : 533 - 542
  • [7] Effects of endothelin receptor antagonism and angiotensin-converting enzyme inhibition on cardiac and renal remodeling in the rat
    Willette, RN
    Minehart, H
    Ellison, J
    Simons, T
    Short, B
    Pullen, M
    Ohlstein, EH
    Nambi, P
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1998, 31 : S277 - S283
  • [8] ETA receptor antagonism, angiotensin type 1 receptor antagonism, angiotensin-converting enzyme inhibition and combined treatments after experimental myocardial infarction in stroke-prone spontaneously hypertensive rats
    Reinecke, A
    Xia, Q
    Dorenkamp, M
    Bitterling, H
    Penz, S
    Storz, C
    Simon, R
    Unger, T
    EUROPEAN HEART JOURNAL, 2003, 24 : 170 - 170
  • [9] Angiotensin-converting enzyme inhibition and angiotensin II antagonism in nondiabetic chronic nephropathies
    Ruggenenti, P
    SEMINARS IN NEPHROLOGY, 2004, 24 (02) : 158 - 167
  • [10] STRUCTURAL-CHANGES AND CYCLIC CMP CONTENT THE AORTA AFTER CALCIUM ANTAGONISM OR ANGIOTENSIN-CONVERTING ENZYME-INHIBITION IN RENOVASCULAR HYPERTENSIVE RATS
    VENIANT, M
    GRAY, GA
    HEUDES, D
    MENARD, J
    CLOZEL, JP
    JOURNAL OF HYPERTENSION, 1995, 13 (07) : 731 - 737